-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Capital Markets Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $19

Benzinga·03/04/2025 14:14:50
Listen to the news
Citizens Capital Markets analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and lowers the price target from $22 to $19.